Compared to controls, patients with MASLD/MASH exhibited significantly lower levels of FGF19, choline, and trimethylamine, while FGF21, galectin-3, irisin, and leptin were elevated. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.